Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 31, 2018. The document serves as a transaction notification regarding a specific corporate action involving the company's Performance Share Plan.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports a single transaction detail:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of shares via dividend re-investment.
- Volume: 1,895 shares.
- Price: £15.766 per share.
- Transaction Date: July 12, 2018.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents a routine administrative transaction where dividends paid on July 12, 2018, were re-invested to acquire shares for the Performance Share Plan, subject to a 2-year holding period.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. The only noted condition is the 2-year holding period applicable to the shares acquired through the dividend re-investment plan.
Key Facts for Investor Verification
- Verify the total number of shares held in the Performance Share Plan to assess the significance of this 1,895 share acquisition.
- Confirm the dividend payment date of July 12, 2018, and the corresponding dividend per share amount to validate the re-investment calculation.
- Note that this filing is a regulatory disclosure of a specific transaction and does not reflect the company's overall financial performance for the quarter or year.